Atherosclerosis
Volume 200, Issue 2 , Pages 410-416 , October 2008

Dietary salt restriction increases plasma lipoprotein and inflammatory marker concentrations in hypertensive patients

  • Edna R. Nakandakare

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • Corresponding Author InformationCorresponding author at: Laboratório de Lípides, Faculdade de Medicina USP. Av. Dr. Arnaldo 455, s/3305, 01246-000 São Paulo, SP, Brazil. Tel.: +55 11 3062 1255; fax: +55 11 3062 1255.
    • ,
  • Ana M. Charf

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • Both the authors contributed equally to this work.
    • ,
  • Flávia C. Santos

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • Both the authors contributed equally to this work.
    • ,
  • Valéria S. Nunes

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Katia Ortega

      Affiliations

    • Hypertension Unit, Nephrology Division of Hospital das Clinicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Ana M.P. Lottenberg

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Décio Mion Jr.

      Affiliations

    • Hypertension Unit, Nephrology Division of Hospital das Clinicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Takamitsu Nakano

      Affiliations

    • Japan Immunoresearch Laboratories Co., Ltd., Takasaki, Gumma, Japan
    • ,
  • Katsuyuki Nakajima

      Affiliations

    • Japan Immunoresearch Laboratories Co., Ltd., Takasaki, Gumma, Japan
    • ,
  • Elbio A. D’Amico

      Affiliations

    • Pro-Sangue Foundation, Hemocentro-SP, Sao Paulo, Brazil
    • ,
  • Sergio Catanozi

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Marisa Passarelli

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Eder C.R. Quintão

      Affiliations

    • Lipids Lab (LIM10), Endocrinology and Metabolism Division of Hospital das Clínicas, Faculty of Medical Sciences of the University of Sao Paulo, Sao Paulo, Brazil

Received 12 November 2007 ,Accepted 20 December 2007.

References 

  1. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16(11):761–770
  2. Jürgens G, Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev. 2004;1:CD004022;(Update of Cochrane Database Syst Rev. 2003;(1):CD004022)
  3. Del Río A, Rodríguez-Villamil JL. Metabolic effects of strict salt restriction in essential hypertensive patients. J Intern Med. 1993;233(5):409–414
  4. Townsend RR, Kapoor S, McFadden CB. Salt intake and insulin sensitivity in healthy human volunteers. Clin Sci (Lond). 2007;113(3):141–148
  5. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995;25(1):30–36
  6. Alderman MH, Cohen H, Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet. 1998;351:781–785
  7. Chrysant GS, Bakir S, Oparil S. Dietary salt reduction in hypertension—what is the evidence and why is it still controversial?. Prog Cardiovasc Dis. 1999;42:23–38
  8. Cohen HW, Hailpern SM, Fang J, Alderman MH. Sodium intake and mortality in the NHANES II follow-up study. Am J Med. 2006;119:275.e7–275.e14
  9. Catanozi S, Rocha JC, Nakandakare ER, et al. The rise of the plasma lipid concentration elicited by dietary sodium chloride restriction in Wistar rats is due to an impairment of the plasma triacylglycerol removal rate. Atherosclerosis. 2001;158:81–86
  10. Catanozi S, Rocha JC, Passarelli M, et al. Dietary sodium chloride restriction enhances aortic wall lipid storage and raises plasma lipid concentration in LDL receptor knockout mice. J Lipid Res. 2003;44:727–732
  11. Vidonho AF, Silva AA, Catanozi S, et al. Perinatal salt restriction: a new pathway to programming insulin resistance and dyslipidemia in adult Wistar rats. Pediatr Res. 2004;56:842–848
  12. Prada PO, Okamoto MM, Furukawa LN, et al. High or low salt diet from weaning to adulthood: effect on insulin sensitivity in Wistar rats. Hypertension. 2000;35:424–429
  13. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. Dietary salt restriction accelerates atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2005;180(2):271–276
  14. Boquist S, Ruotolo G, Tang R, et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation. 1999;100:723–728
  15. Bachorik PS, Albers S. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 1986;129:78–100
  16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem Winston-Salem. 1972;18:499–502
  17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495
  18. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicrons triglycerides clearance. J Lipid Res. 2003;44:455–463
  19. Redgrave TG, Roberts DCK, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975;65:42–49
  20. Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apoA-1 immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53–71
  21. Bernik MM, Heimann JC, Nakandakare ER, et al. Effects of hydrochlorothiazide and propranolol treatment on chylomicron metabolism in hypertensive objects. Can J Physiol Pharmacol. 2005;83:617–623
  22. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 2002;40:872–879
  23. Petrie JR, Morris AD, Minamisawa K, et al. Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:1552–1557
  24. Perry CG, Palmer T, Cleland SJ, et al. Decreased insulin sensitivity during dietary sodium restriction is not mediated by effects of angiotensin II on insulin action. Clin Sci (Lond). 2003;105:187–194
  25. Grey A, Braatvedt G, Holdaway I. Moderate dietary salt restriction does not alter insulin resistance or serum lipids in normal men. Am J Hypertens. 1996;9:317–322
  26. Donovan DS, Solomon CG, Seely EW, Williams GH, Simonson DC. Effects of sodium intake on insulin sensitivity. Am J Phys. 1993;264:E730–E734
  27. Gomi T, Shibuya Y, Sakurai J, et al. Strict dietary sodium reduction worsens insulin sensitivity by increasing sympathetic nervous activity in patients with primary hypertension. Am J Hypertens. 1998;11:1048–1055
  28. Prada PO, Coelho MS, Zecchin HG, et al. Low salt intake modulates insulin signaling, JNK activity and IRS-1ser307 phosphorylation in rat tissues. J Endocrinol. 2005;185:429–437
  29. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension. 2001;38:884–890
  30. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622–625
  31. Bosch J, et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005;112:1339–1346
  32. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783–1790
  33. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(Suppl. 6A):9S–16S
  34. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–2951
  35. Verma S, Deraraj S, Jialal I. Is C-reactive protein an innocent bystander or proactive culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135–2150
  36. Ferrario CM, Strawn WB. Role of rennin–angiotensin–aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121–128
  37. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the rennin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76–81
  38. Ran J, Hirano T, Fukui T, et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metab Clin Exp. 2006;55:478–488
  39. Kim S, Urs S, Massiera F, et al. Effects of high-fat diet, angiotensinogen (agt) gene inactivation, and targeted expression to adipose tissue on lipid metabolism and renal gene expression. Horm Metab Res. 2002;34:721–725
  40. Lowe GD, et al. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol. 2004;24:1529–1534
  41. Junker R, Heinrich J, Schulte H, Erren M, Assmann G. Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Munster study. J Hypertens. 1998;16:917–923
  42. Lechi C, Gaino S, Zuliani V, et al. Elevated plasma fibrinogen levels in patients with essential hypertension are related to vascular complications. Int Angiol. 2003;22:72–78
  43. Makris TK, Stavroulakis GA, Hatzizacharias AN, et al. Parental history of hypertension is associated with coagulation-fibrinolytic balance disorders. Thromb Res. 2003;111:45–49
  44. Donders SH, Lustermans FA, Van Wersch JW. Coagulation factors and lipid composition of the blood in treated and untreated hypertensive patients. Scand J Clin Lab Invest. 1993;53:179–186
  45. Phillips GB, Jing TY, Resnick LM, et al. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens. 1993;11:699–702
  46. Marques-Vidal P, Montaye M, Haas B, et al. Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME study. J Hum Hypertens. 2000;14:511–518
  47. Piche ME, Lemieux S, Weisnagel SJ, et al. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol. 2005;96:92–97
  48. Wannamethee SG, Lowe GD, Shaper AG, et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis. 2005;181:101–108

PII: S0021-9150(08)00006-3

doi: 10.1016/j.atherosclerosis.2007.12.034

Atherosclerosis
Volume 200, Issue 2 , Pages 410-416 , October 2008

Article Tools

* Image Usage & Resolution